Overview
Dr. Dylan Kahl is a patent agent at Faegre Drinker, where he is a member of the intellectual property practice. Dylan earned his Ph.D. in Medicinal Chemistry at the University of Michigan. His practice focuses on patent prosecution and intellectual property counseling, serving clients in a wide range of technology fields, including the pharmaceutical and biotechnology industries.
Dylan has experience in providing patent counseling for companies and venture capital firms focusing on small-molecule and other therapeutic inventions in the fields of chemistry, medicinal chemistry, pharmaceuticals, biochemistry and biotechnology. His skills include developing and implementing patent strategies, patent prosecution and patent diligence for venture financings, public offerings and other transactions.
Patents & Intellectual Property Experience
Dylan manages patent portfolios for therapeutic companies and has helped secure funding for numerous clients. He has extensive experience drafting patent applications, and foreign and domestic office action responses for various chemistry and biochemistry applications, such as in the life sciences, biopharmaceutical and clean tech sectors. Specifically, Dylan’s drafting experience includes: small molecule pharmaceuticals, mRNA and gene therapies, protein and cell therapies, pharmaceutical formulations, nucleic acid and protein sequencing, synthetic biology, biomaterials, food technologies, energy production and storage materials, biomaterials, and metals.
He is proficient at developing and communicating with clients on their short- and long-term IP strategies, including strategies to help secure funding and provide patent portfolio longevity. A reliable team player who strives for efficient task management, Dylan also builds trust and develops strong relationships with clients and their working teams.
Prior Technical Experience
During his doctoral work at the University of Michigan, Dylan studied under Dr. Scott D. Larsen at the Vahlteich Medicinal Chemistry Core, where he worked on a variety of projects related to small-molecule drug development, including the design and synthesis of potent small-molecule antifibrotic agents from hit to lead, and the production of many successful affinity pull-down probes for target identification studies. Given his background, Dylan has a strong understanding of drug development and technological innovations spanning the fields of chemistry and biology.
Related Legal Services
Related Industries
Credentials
Bar Admissions
U.S. Patent and Trademark Office
Education
University of Michigan
Ph.D. in Medicinal Chemistry (2018)
Arizona State University
B.S. in Biochemistry (2014)
Insights & Events
Other Perspectives
- 5-Aryl-1,3,4-oxadiazol-2-ylthioalkanoic Acids: A Highly Potent New Class of Inhibitors of Rho/Myocardin-Related Transcription Factor (MRTF) / Serum Reponse Factor (SRF)-Mediated Gene Transcription as Potential Antifibrotic Agents for Scleroderma
Co-author, 62(9) Journal of Medicinal Chemistry 4350-69 (May 9, 2019) - Identification of Pirin as a Molecular Target of the CCG-1423/CCG-203971 Series of Antifibrotic and Antimetastatic Compounds
Co-author, 2(2) ACS Pharmacology & Translational Science 92-100 (2019) - Discovery of Pirin as a Molecular Target for a Novel Series of Rho/MRTF/SRF Pathway Inhibitors With Anti-fibrotic Activity
Speaker, 36th National Medicinal Chemistry Symposium, Nashville, Tenn. (April 29-May 2, 2018) - Development of Affinity Probes for Identification of the Molecular Target for a Novel Series of Rho/MRTF/SRF-Mediated Gene Transcription Inhibitors
Speaker, 254th American Chemical Society National Meeting, Washington, D.C. (Aug. 20-24, 2017)